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A number of reports have indicated that liver damage is a significant 
complication in recipients of renal homografts [2, 3, 6-8, 11]. Studies of 
patients treated at the University of Colorado Medical Center and the Denver 
Veterans Administration Hospital show that the incidence of posttrans-
plantation liver injury may be even higher than has been generally believed. 
Case Material 
Renal homotransplantation was performed in 185 patients between March 
1962 and April 1968. None of the recipients, who were aged 3 to 55 years, had 
known liver disease prior to transplantation, although in 39 of the earlier 
cases adequate biochemical tests were not obtained preoperatively to establish 
this fact. In the other 146, hepatic function was studied before operation and 
at frequent intervals afterward. With the growing realization of the high 
incidence of liver disease in this kind of patient, a standard profile of labora-
tory determinations was routinely used. The tests performed included total 
serum proteins, protein electrophoresis, serum bilirubin, alkaline phos-
phatase, serum glutamic-oxaloacetic transaminase (SGOT), serum glutamic-
pyruvic transaminase (SGPT), and prothrombin time. Bromsulphalein 
(BSP) was determined in a number of cases. 
Although histopathologic specimens from the entire group will be included, 
the major portion of this report will be concerned with the 146 cases in which 
liver function was assessed before and after transplantation. Of the latter 
patients, 104 received kidneys from related living donors, 24 from unrelated 
living donors, and 18 from cadavers. All were treated with prednisone and 
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azathioprine, and the last 66 were also given horse antihuman-lymphocyte 
globulin (ALG). Rejection crises were treated with increased doses of pred-
nisone and with actinomycin C or local radiotherapy to the transplant. More 
than 95 % of the patients underwent bilateral nephrectomy and splenectomy 
at the same time as the transplantation; 30 patients also had thymectomy 
at some time earlier. 
There were a number of other factors which were examined because of their 
possible role in the genesis of posttransplantation liver disease. All but 2 of 
the recipients were prepared for operation with hemodialysis. Blood trans-
fusions were given at some time to every patient either before or during 
operation; after transplantation transfusions were rarely required. A note 
was also made of the type of anesthesia used, any incidence of intraoperative 
hypoxia or hypotension, and the many nonimmunosuppressive agents ad-
ministered postoperatively. These included antihypertensive, chemothera-
peutic, antibiotic, antacid, analgesic, narcotic, diuretic, laxative, and anti-
histaminic drugs. 
Results 
THE INCIDENCE AND TIMING OF LIVER MALFUNCTION 
Eighty-eight (60%) of the 146 patients completely studied with liver 
chemistries developed abnormalities in one or more of the tests mentioned 
earlier. The liver dysfunction appeared within the first 6 months after trans-
plantation in the majority of these recipients (Fig. IA). In most instances the 
changes were transient and mild, but in some they were marked and per-
sistent. 
There were 20 cases in which the hepatic disease was classified as severe as 
judged by the liver chemistries to be discussed below. In more than two-
thirds of these patients a diagnosis of a liver complication was established 
within the very early postoperative period, but in a minority the evidence of 
hepatic damage appeared much later (Fig. IB). Four of the 20 patients died 
as the direct consequence of acute hepatic failure from 5 to 18 months after 
transplantation; in 6 other cases a less fulminant kind of hepatic disease was 
an important contributory cause of death. 
THE HEPATIC FUNCTION ABNORMALITIES 
The derangements in liver function were highly variable from case to case 
and were accompanied by clinical symptoms in only a small minority. For 
example, it was extremely common to have elevations in the serum trans-
aminases (Fig. 2) at a time of apparent good health and in the absence of 
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FIG. 1. Time of onset of liver damage. 
jaundice or other alarming findings. Even the appearance of hyperbiliru-
binemia was not necessarily a bad prognostic sign since 52 patients had icterus 
(Fig. 3) of 1.5 mg/lOO ml or greater, but in most cases this was transient. 
The increased bilirubin concentration was usually a combination of the con-
jugated and unconjugated forms and was almost invariably accompanied by 
increases in alkaline phosphatase (Fig. 4). 
There were often declines in serum protein concentrations, sometimes to 
extraordinarily low levels (Fig. 5). However, the significance of these changes 
in relation to liver disease was frequently difficult to analyze because of the 
complex clinical situation. Thus, some of these patients had persistent pro-
teinuria as a contributory factor, and in many others important underlying 
causes were poor diet or high dose steroid therapy. Nevertheless, a hepatic 
etiology was undoubtedly at least partially responsible in some since there 
were also coincident depressions in the prothrombin time (Fig. 6) and a 
number of the same patients had marked BSP retention (Fig. 7); there was a 
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FIG. 2. Serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamic-pyruvic 
transaminase (SGPT) levels in renal homograft recipients. The SGOT was elevated in 59 % 
of these patients, and the SGPT in 51 %. The normal values are less than 40 international 
units (IU) per liter. The levels shown here and in all the subsequent illustrations are the most 
abnormal observed in any given patient. 
more than 5 % BSP retention in 31 of the 39 patients in which it was deter-
mined. 
THE EFFECT OF ALG THERAPY ON LIVER DISEASE 
Fifty-two (65 %) of the 80 patients treated with azathioprine and prednisone 
before June, 1966, developed evidence of liver damage. All 4 of the fatalities 
caused by acute hepatic failure were in this group. 
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FIG. 3. Total bilirubin was elevated above 1.0 mg/1oo ml in 52 of the 143 patients 
studied. The normal values are less than 1.0 mg/1oo ml. 
In the next 2 years, horse ALG was used as an adjuvant immunosuppressive 
agent in combination with reduced doses of azathioprine and prednisone [12]. 
Thirty-six (54 %) of the 66 patients treated in the latter period also had 
some findings of hepatic damage, but generally to a less severe degree and 
never with a fatal outcome. Consequently, it has been our conclusion that 
the magnitude of the problem has been distinctly less since the addition of 
ALG to the immunosuppressive regimen. 
HISTOPATHOLOGIC FINDINGS 
Forty-two livers were studied either at autopsy or as the result of needle 
biopsies during life. The overall impression was that the more severe histologic 
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FIG. 4. Alkaline phosphatase was elevated in 65 % of 132 patients after renal trans-
plantation at some time in the postoperative course. The normal values are 14-38 IU. 
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FIG. 5. Total serum proteins were markedly reduced in most patients. The values given 
are the lowest ever observed in any given case. (A) Total. (B) Albumin. 
findings were in the patients who had manifested the most marked derange-
ments in liver function. 
The finding of increased iron associated with diastase-resistant periodic 
acid-Schiff-positive granules in hepatocytes and Kupffer cells described by 
Hill et al. [5] was confirmed in almost all cases. The accumulations of iron 
were very large in 6 cases and not associated with other prominent 
changes. 
Significant fatty metamorphosis was present in 18 of the livers; it was mild 
to moderate in 10 and severe in 8. It was often associated with nonspecific 
degenerative changes in hepatocytes or variable central necrosis. Slight bile 
stasis without other signs of severe liver injury was found in 5 instances. In 17 
other autopsy cases, the same nonspecific pattern of injury was present but 
the frequency and severity of the lesions were lower. 
Massive hepatic necrosis consistent with viral hepatitis was present in 4 
livers. Moderate to severe central necrosis not accompanied by passive 
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FIG. 6. Prothrombin times were below 40% at some time in 22 of the 119 patients in 
which it was estimated. 
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FIG. 7. Bromsulphalein (BSP) retention of greater than 6% after 45 minutes was 
observed in 31 of 39 patients in which this test was performed. The abnormal values usually 
improved with the passage of time. 
congestion was found in 5 other cases, and was accompanied by bile stasis in 
one. The cause of this injury was not apparent; it may have represented a 
milder form of massive necrosis. A variable degree of portal fibrosis was 
found in 3 cases, and in many others there was a scant to moderate infiltrate 
of chronic inflammatory cells in the portal triads. One case demonstrated 
typical post-hepatitic cirrhosis. 
In contrast to the great frequency and severity of pulmonary infections in 
these patients, lesions attributable to infectious disease other than viral 
hepatitis were rare. There were 3 livers which contained the inclusions of 
cytomegalovirus. One case of hepatic histoplasmosis and one of hepatitis 
caused by a toxoplasma-like organism were found. Minute foci of hepatic 
necrosis without demonstrable organisms were seen in 2 cases. One patient 
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with widespread reticulum cell sarcoma had multiple tumor masses in the 
liver. 
Discussion 
The data from this series indicate that detectable liver damage occurs in the 
majority of patients after renal homotransplantation. Unfortunately, it may 
be impossible to determine the etiology of the hepatic dysfunction in any 
given case. It seems likely that the causative factors are variable. 
A significant number of these patients were probably the victims of viral 
hepatitis. Statistically, the renal transplant recipient should be at high risk 
from this kind of infectious complication since he is usually exposed to 
multiple blood transfusions as well as extracorporeal hemodialysis before 
operation. Hampers et al. [4] found that 7 % of nontransplantation patients 
who received one pint of blood and virtually all of those who received 6 or 
more transfusions developed anicteric hepatitis. It might be speculated that 
because of the immunosuppression and immunologic crippling imposed on 
the transplant recipient he would be prone to exhibit more serious mani-
festations of the disease. 
The foregoing explanation for posttransplantation "hepatitis" could be 
well supported in a number of cases in this series. First, the onset of liver 
dysfunction often, although not invariably, occurred within the known in-
cubation period (approximately 100 days) of serum hepatitis. Second, the 
clinical presentation and pathologic findings were often highly suggestive of 
this diagnosis. Finally, 4 members of the surgical staff who cared for these 
patients developed the same disease at about the same time or slightly after-
ward. The propensity of the liver to develop infectious complications during 
intensive immunosuppression can also be illustrated by the fact that several 
of the organs examined histopathologically had evidence of invasion by 
cytomegalovirus or fungi. 
It is highly unlikely, however, that viral hepatitis or other infections can be 
indicted as the universal cause of the liver dysfunction after renal homo-
transplantation, as was emphasized by Hamburger et al. [3] and in earlier 
publications from our own institutions [8, 11]. It is well known from animal 
research that both azathioprine and prednisone can cause liver injury [9, 10] 
although the extrapolation of this kind of information to man has not been 
well supported by the kind of pathologic studies carried out by Hill, Porter, 
and Massion [5]. Nevertheless, it was pointed out above that the majority of 
hepatic complications occur during the first several postoperative months at a 
time when the most stringent immunosuppressive treatment is required to 
prevent rejection. A situation of double jeopardy may result not only from 
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unmasked viral infection, but also from the inherent hepatotoxicity of the 
drugs. 
Other pharmacological agents often used in the care of these patients have 
also been on occasion reported to cause liver injury. These include the anti-
hypertensive drug ex-methyl-DOPA (Aldomet) and the antibiotics tetracycline, 
prostaphlin, methicillin, ampicillin, gantrisin, and amphoteracin B [1]. In 
addition some of the anesthetics used for these patients apparently can cause 
hepatic damage. Of the latter halothane has received the most attention, but 
there were no instances in our series in which the use of this or other anesthetic 
agents was followed by acute liver injury. 
Vague though the conclusions may be about the presumed multiple 
etiologies of liver disease in patients receiving renal homografts under 
immunosuppressive therapy, it is crucial for obvious practical reasons to have 
an idea of the frequency of this kind of complication before embarking on 
trials of liver transplantation. With the latter procedure the differential 
diagnosis and proper management could become hopelessly confused by the 
coexistence of hepatic rejection and liver injury from other causes. The present 
study has demonstrated the number of times with which this perplexing 
picture may potentially have to be dealt. 
With the onset of jaundice in renal homograft recipients, it may not be 
necessary to make adjustments in the immunosuppressive therapy providing 
the hepatic complication is not too severe or protracted. If, however, the liver 
disease is major and prolonged, it is often advisable to reduce the vigor of 
treatment, especially of azathioprine, and to accept the possible risk of 
homograft repudiation. 
There are two reasons for this. First, it was noted several years ago [11] 
that the hyperbilirubinemia in such patients tended to decrease coincident 
with reductions in azathioprine dosage. Second, patients with serious hepatic 
injury are much more apt to develop bone marrow depression, presumably 
because the hepatic pathway of detoxification of azathioprine is partially lost. 
Efforts to continue preexisting doses of azathioprine may therefore be 
dangerous. 
Sum.m.ary 
Liver damage in renal homotransplant recipients is more common than is 
generally believed. It occurred in 60 % of 146 patients studied and was severe 
in 13.7 %. Common causes of liver damage are viral hepatitis and/or the use of 
immunosuppressive and other potentially hepatotoxic drugs. The incidence of 
major liver complications has been less since the introduction of horse 
antihuman-lymphocyte globulin as an adjuvant immunosuppressive agent. 
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